Atenolol

Human medicines European public assessment report (EPAR): Corlentor, ivabradine, Date of authorisation: 25/10/2005, Revision: 27, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Blood pressure, Medical Subject Headings, Heart failure, Marketing, Meal, Liver, INN, Risk, Cardiogenic shock, Woman, Heart rate, ATC, BPM, Blood, International, Moyamoya disease, Disease, NYHA, Language, Heart, Death, Angina, Coronary artery disease, Tablet, Select, Human, Patient, Facial muscles, Anatomy, Atenolol, IIA, Jaw, Exercise, Amlodipine, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Corlentor, ivabradine, Date of authorisation: 25/10/2005, Revision: 27, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Corlentor, ivabradine, Date of authorisation: 25/10/2005, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Procoralan, ivabradine, Date of authorisation: 25/10/2005, Revision: 22, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Blood pressure, Medical Subject Headings, Heart failure, Marketing, Meal, Liver, Agency, INN, Risk, Cardiogenic shock, Woman, Heart rate, ATC, BPM, Blood, International, Disease, NYHA, Language, Heart, Death, Angina, European Medicines Agency, Coronary artery disease, Tablet, Select, Human, Patient, Anatomy, Medicine, Atenolol, IIA, Jaw, Exercise, Amlodipine, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Procoralan, ivabradine, Date of authorisation: 25/10/2005, Revision: 22, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Procoralan, ivabradine, Date of authorisation: 25/10/2005, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Ivabradine Anpharm, ivabradine, Date of authorisation: 08/09/2015, Revision: 10, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Blood pressure, Medical Subject Headings, Heart failure, Marketing, Meal, Liver, Agency, INN, Risk, Cardiogenic shock, Woman, Heart rate, ATC, BPM, Blood, International, Disease, NYHA, Ivabradine, Language, Heart, Death, Angina, European Medicines Agency, Coronary artery disease, Tablet, Select, Human, Patient, Facial muscles, Anatomy, Atenolol, IIA, Jaw, Exercise, Amlodipine, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Ivabradine Anpharm, ivabradine, Date of authorisation: 08/09/2015, Revision: 10, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Ivabradine Anpharm, ivabradine, Date of authorisation: 08/09/2015, Revision: 10, Status: Authorised

Unibloc Hygienic Technologies Acquires Metaltech Precision Engineers, An Experienced Provider of CNC Machining Services

Retrieved on: 
星期四, 三月 9, 2023
Engineering, Chemicals, Plastics, Manufacturing, Construction & Property, Building Systems, Other Manufacturing, Machinery, UHT, Poultry, Meat, Specialization, Acquisition, CNC, Partnership, Food, GA, Pine River Capital Management, Investment, Transport, Metaltech, Atenolol, Bolney

Unibloc Hygienic Technologies (UHT, www.unibloctech.com ), a global provider of hygienic positive displacement pumps, air-operated double diaphragm (AODD) pumps, drum pumps, and other flow control products, today announced the acquisition of Metaltech Precision Engineers Ltd. Metaltech, a UK-based CNC machining services provider, enjoys a nearly 50-year operating history as a critical supply chain partner to the hygienic flow control industry.

Key Points: 
  • Unibloc Hygienic Technologies (UHT, www.unibloctech.com ), a global provider of hygienic positive displacement pumps, air-operated double diaphragm (AODD) pumps, drum pumps, and other flow control products, today announced the acquisition of Metaltech Precision Engineers Ltd. Metaltech, a UK-based CNC machining services provider, enjoys a nearly 50-year operating history as a critical supply chain partner to the hygienic flow control industry.
  • Metaltech, founded in 1976, is a precision engineering and CNC machining services vendor with a specialization in the hygienic flow control sector.
  • Metaltech provides machining for a wide range of UHT’s hygienic pumps that serve the food, beverage, bakery/confection, meat and poultry, brewery, pharmaceutical and transportation markets globally.
  • This is the third acquisition in 18 months for Unibloc Hygienic Technologies, a May River Capital portfolio company.

Unibloc Hygienic Technologies Expands Capacity with CNC Machining Investment in UK

Retrieved on: 
星期四, 十二月 8, 2022
Other Manufacturing, Engineering, Chemicals, Plastics, Oil, Gas, Manufacturing, Biotechnology, Energy, Machinery, Health, Food, Transport, Poultry, Knowledge, UHT, Cosmetics, Meat, Atenolol, Investment, Matsuura, Workforce, CNC, Renewable energy, Machine shop, Bolney, Franc Flotron

Unibloc Hygienic Technologies, Inc. (UHT), a global leader in hygienic positive displacement pumps, AODD pumps, drum pumps, and other flow control products, has expanded production capacity at its Bolney, UK facility with a significant investment in additional machining technology.

Key Points: 
  • Unibloc Hygienic Technologies, Inc. (UHT), a global leader in hygienic positive displacement pumps, AODD pumps, drum pumps, and other flow control products, has expanded production capacity at its Bolney, UK facility with a significant investment in additional machining technology.
  • The investment continues UHTs ongoing strategy of increasing production capacity to reduce production lead times and improve customer service.
  • The Matsuura is a 12-pallet, four-axis machining center offering the capacity to replace three older machines with one, while increasing productivity.
  • An industry leader in flow control technology and performance, Unibloc Hygienic Technologies offers precision-engineered positive displacement pumps, AODD pumps, drum pumps, and other highly engineered products for demanding hygienic flow control applications.

Global 3D Printed Drugs Market Report 2022: Drawbacks of Traditional Pharmaceutical Operations Fueling Growth - ResearchAndMarkets.com

Retrieved on: 
星期四, 十一月 3, 2022
Health, Pharmaceutical, United Nations, 3D, Growth, Amlodipine, Ageing, Hearing, Asthma, CAGR, Industry, Neurology, Hydrochlorothiazide, FDM, Irbesartan, Illegal drug trade, Tablet, Arthritis, Health, First Nations in Ontario, Stereolithography, Nanoparticle, Prevalence, Conditional sentence, Capsule, Diabetes, SLA, Technology, Photopolymer, Atenolol, Person, Cancer, Solution, 3D printing, Pharmaceutical industry, Levetiracetam

The "Global 3D Printed Drugs Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global 3D Printed Drugs Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global 3D printed drugs market is anticipated to grow at a CAGR of 9.1% during the forecast period.
  • 3D-printed drugs may be useful for orphan drugs and/or personalized medications as these drugs are produced in a small amount.
  • The market for 3D printed drugs is being driven by the drawbacks of traditional pharmaceutical unit operations across the globe.

Unibloc Pump Rebrands to Unibloc Hygienic Technologies

Retrieved on: 
星期二, 四月 26, 2022
Engineering, Chemicals, Plastics, Other Manufacturing, Manufacturing, Family, Meat, CEO, Atenolol, Transport, Business, UHT, Food, Poultry, Industry, Hydraulic machinery, Industrial design

Unibloc Pump, a leader in positive displacement pumps and other highly engineered products for demanding hygienic flow control applications, has rebranded to Unibloc Hygienic Technologies (UHT).

Key Points: 
  • Unibloc Pump, a leader in positive displacement pumps and other highly engineered products for demanding hygienic flow control applications, has rebranded to Unibloc Hygienic Technologies (UHT).
  • Standard Pump: Georgia-based manufacturer of hygienic and industrial process pumps, including drum pumps and other fluid handling equipment (acquired by Unibloc Pump in December 2021)
    "All three companies Unibloc, Flotronic, and Standard Pump have each built a leading reputation for quality manufacturing, innovative design and excellent customer service, said Chris Stevens, CEO of Unibloc Hygienic Technologies.
  • Each companys products are represented now as subsidiary brands under the Unibloc Hygienic Technologies umbrella, with identities that tie them together.
  • An industry leader in flow control technology and performance, Unibloc Hygienic Technologies offers precision-engineered positive displacement pumps, AODD pumps, drum pumps, and other highly engineered products for demanding hygienic flow control applications.

CSOB Partners with Diebold Nixdorf to Achieve its Vision of Tellerless Branches

Retrieved on: 
星期一, 二月 14, 2022
NYSE, Czech Republic, KBC Bank, Housing, ATM, DBD, Human Touch, CEE, SME, DN, CSOB, Ownership, Technology, Somatosensory system, Compliance, Insurance, Diebold Nixdorf, SOB, Partnership, Machine learning, Investment, Digital, Cloud computing, Cryptocurrency, Bank, Atenolol

Diebold Nixdorf is responsible for all operations, including availability, compliance, security, cash and transaction management while continuously enhancing the end-user experience.

Key Points: 
  • Diebold Nixdorf is responsible for all operations, including availability, compliance, security, cash and transaction management while continuously enhancing the end-user experience.
  • The partnership between CSOB and Diebold Nixdorf began in 2001 and has grown and evolved over the past 20 years.
  • With more than 4.2 million clients, CSOB leads the digital transformation in the banking sector across Europe.
  • CSOB's fleet is comprised entirely of Diebold Nixdorf devices, of which nearly 200 are already DN Series with cash recycling technology to optimize cash handling and reduce costs.

AstraZeneca to Showcase Leadership in Treating Type 2 Diabetes and Cardiorenal Complications at ADA 2020

Retrieved on: 
星期四, 六月 11, 2020
FDA, Health, Diabetes, Clinical trials, Pharmaceutical, Cardiology, RTT, Diabetes, Organ systems, Medical specialties, Endocrine system, Dapagliflozin, Diabetic ketoacidosis, SGLT2 inhibitor, Type 1 diabetes, Sodium-glucose transport proteins, Type 2 diabetes, Atenolol

Acute kidney injury requiring hospitalization and dialysis has been reported in patients with type 2 diabetes receiving SGLT2 inhibitors, including FARXIGA.

Key Points: 
  • Acute kidney injury requiring hospitalization and dialysis has been reported in patients with type 2 diabetes receiving SGLT2 inhibitors, including FARXIGA.
  • After initiating therapy, monitor for signs and symptoms of hypotension and renal function
    Ketoacidosis in Diabetes Mellitus has been reported in patients with type 1 and type 2 diabetes receiving FARXIGA.
  • While use is not limited to this setting, the efficacy of ticagrelor was established in a population with type 2 diabetes.
  • Should not be used to treat type 1 diabetes or diabetic ketoacidosis
    Not studied in patients with a history of pancreatitis.

Study Finds Seniors with COVID-19 Taking Hypertension Medication at Lower Risk of Hospitalization, Clinical Trial to Follow Immediately

Retrieved on: 
星期二, 五月 19, 2020
Insurance, Technology, University, Practice Management, Pharmaceutical, Education, Managed care, Professional services, Seniors, Infectious diseases, Hospitals, Clinical trials, Biotechnology, Software, Consumer, Health, ACE inhibitors, Enzymes, Drugs, RTT, Branches of biology, Prodrugs, Angiotensin-converting enzyme, Hypertension, Atenolol, Antihypertensive drug

A study completed by UnitedHealth Group (NYSE: UNH) with the Yale School of Medicine found that older COVID-19 patients with hypertension taking angiotensin-converting enzyme (ACE) inhibitors had a lower risk of COVID-19 hospitalization.

Key Points: 
  • A study completed by UnitedHealth Group (NYSE: UNH) with the Yale School of Medicine found that older COVID-19 patients with hypertension taking angiotensin-converting enzyme (ACE) inhibitors had a lower risk of COVID-19 hospitalization.
  • A pragmatic clinical trial will be a critical next step.
  • The use of ACE inhibitors was associated with an almost 40% lower risk of COVID-19 hospitalization for Medicare Advantage patients.
  • Use of the medication was not found to reduce mortality risk in individuals once hospitalized with COVID-19.